Patents Examined by Dong Jiang
  • Dual specific binding proteins directed against IL-13 and IL-17
    Patent number: 9120870
    Abstract: Engineered multivalent and multispecific binding proteins that bind IL-13 and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: September 1, 2015
    Assignee: AbbVie Inc.
    Inventors: Chung-Ming Hsieh, Tariq Ghayur, Carrie L. Goodreau
  • Methods of immunoregulation by albumin neo-structures
    Patent number: 9120874
    Abstract: The present invention relates to isolated protein sequences that correspond to cell binding peptides, fragments, neo-structures and/or neo-epitopes of a normally occurring serum protein present in human tissue, wherein the peptide, fragment, neo-structure and/or neo-epitope has an immunoregulatory activity and is the result of either an enhanced proteolytic activity and/or conformational changes in a tissue, or a malignant tumour. In the present patent application, a common structure of several of these peptides, fragments, neo-structures and/or neo-epitopes, having immunoregulatory activity by binding to receptors on immune cells, has been identified. The present invention further also relates to monoclonal and/or polyclonal antibodies directed to a cell binding fragment of a normally occurring serum protein present in human tissue, as described above.
    Type: Grant
    Filed: May 8, 2008
    Date of Patent: September 1, 2015
    Assignee: CANIMGUIDE THERAPEUTICS AB
    Inventors: Leif Hakansson, Birgitta Clinchy
  • Methods for making antibody molecules having specificity for human IL-6
    Patent number: 9096668
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: August 4, 2015
    Assignee: UCB PHARMA S.A.
    Inventors: Richard Evan Gelinas, Mitra Choudhury Singhal, Yi Zhang, Andrew George Popplewell, Ralph Adams
  • Method for screening inhibitors of interleukin-32 (IL-32)
    Patent number: 9045559
    Abstract: The present invention relates to methods of screening for modulators of interleukin 32 (IL-32), to modulators of IL-32 and to their use.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: June 2, 2015
    Assignees: Yeda Research and Development Co. Ltd, The Regents of the University of Colorado
    Inventors: Daniela Novick, Menachem Rubinstein, Charles A. Dinarello, Soo-Hyun Kim
  • Antibodies specific to IL-17A and IL-17F
    Patent number: 9045537
    Abstract: The present invention relates neutralizing epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: June 2, 2015
    Assignee: UCB PHARMA SA
    Inventors: Thomas Allen Ceska, Alistar James Henry, Jiye Shi
  • DNA encoding antibody molecules which bind IL-17A and IL-17F
    Patent number: 9034600
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: May 19, 2015
    Assignee: UCB Biopharma SPRL
    Inventors: Ralph Adams, Terence Seward Baker, Alastair David Griffiths Lawson
  • Antibodies that bind to IL-23
    Patent number: 9023358
    Abstract: The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: May 5, 2015
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Daniel Scott Girard, Kristine Kay Kikly
  • Antagonists of IL-17A, IL-17F, and IL-23P19
    Patent number: 8992922
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: March 31, 2015
    Assignee: ZymoGenetics, Inc.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • Antibodies to hepatocyte growth factor activator
    Patent number: 8969528
    Abstract: The invention provides methods and compositions for modulating hepatocyte growth factor activator function.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: March 3, 2015
    Assignee: Genentech, Inc
    Inventors: Daniel K. Kirchhofer, Yan Wu
  • Methods of diagnosing and treating pulmonary diseases or disorders
    Patent number: 8961965
    Abstract: The present disclosure provides methods of diagnosing a subject as having a pulmonary disease or disorder, e.g., an eosinophilic disease or disorder based on the determination of white blood cell ratios. The disclosure also provides white blood cell ratio-based methods of treating, prognosing, or monitoring a pulmonary disease or disorder, as well as methods of methods of predicting a dosage regimen, identifying a candidate therapeutic agent, identifying a patient as a candidate for a therapeutic agent, and methods of designing a personalized therapy.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: February 24, 2015
    Assignee: MedImmune, LLC
    Inventors: David L Gossage, Deepak B. Khatry, Gregory P. Geba, Nestor Molfino, Joseph M. Parker
  • Cells expressing anti-GD2 antibodies and methods related thereto
    Patent number: 8956832
    Abstract: Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: February 17, 2015
    Assignee: Morphotek, Inc.
    Inventors: Nicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Wolfgang Ebel, Yuhong Zhou
  • Bispecific antibodies to IL-23 and IL-17A/F
    Patent number: 8945553
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: February 3, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
  • Method for detecting human BPLP protein or a maturation product thereof
    Patent number: 8895251
    Abstract: The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: November 25, 2014
    Assignee: Institut Pasteur
    Inventors: Catherine Rougeot, Jean-Francois Huaulme, Marie-Noelle Ungeheuer, Anne Wisner, Evelyne Dufour
  • IL-17 receptor antibody formulation
    Patent number: 8883151
    Abstract: The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: November 11, 2014
    Assignee: Kirin-Amgen, Inc.
    Inventors: Dingjiang Liu, Holly Zhuohong Huang, David Andrew Martin, Christopher Boyd Russell, David H. Salinger, Scott Walter Baumgartner, Christopher J. Endres
  • Monoclonal antibodies to fibrin
    Patent number: 8877195
    Abstract: The present invention provides an isolated antibody that binds a fibrin or fibrinogen ?C domain. In various aspects, the antibody inhibits microglial adhesion to the fibrin or fibrinogen ?C domain, inhibits Mac-1 binding to the fibrin or fibrinogen ?C domain, and/or suppresses clinical symptoms of Experimental Autoimmune Encephalomyelitis (EAE). Various methods of using the antibodies, pharmaceutical compositions, kits, vectors, cells comprising the vectors, and antibody generating methods are provided.
    Type: Grant
    Filed: March 20, 2012
    Date of Patent: November 4, 2014
    Assignee: The Regents of the University of California
    Inventor: Katerina Akassoglou
  • Polynucleotides encoding antibodies that bind both IL-17A and IL-17F
    Patent number: 8871467
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: October 28, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
  • Antibodies to IL-17A and uses thereof
    Patent number: 8865166
    Abstract: Binding members, especially antibody molecules, for interleukin 17 (IL-17). The binding members are useful for the treatment of disorders associated with interleukin 17 such as rheumatoid arthritis.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: October 21, 2014
    Assignee: MedImmune Limited
    Inventors: Duncan Cochrane, Caroline Russell, Matthew Sleeman, Fraser Welsh, Caroline Langham, Maurice Needham, Patrick Dufner
  • Neutralising antibody molecules having specificity for human IL-17
    Patent number: 8865167
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Grant
    Filed: December 9, 2012
    Date of Patent: October 21, 2014
    Assignee: UCB Pharma, S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • Methods for treating disease using an anti-IL-21 receptor antibody
    Patent number: 8790643
    Abstract: Monoclonal antibodies to the IL-21 receptor and multimeric complexes comprising the IL-21 receptor; including monoclonal antibodies to the heterodimeric receptor, IL-21/IL-2R?; have been prepared. The invention also describes a method of producing said antibodies. And, the invention also describes a method of treatment comprising using said antibodies to suppress an immune response.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: July 29, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Pallavur V. Sivakumar, Stephen R. Jaspers
  • Exendin variant peptides
    Patent number: RE45313
    Abstract: The present invention relates to novel peptide conjugates which have increased stability and are useful in the treatment of excess levels of blood glucose.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: December 30, 2014
    Assignee: Zealand Pharma A/S
    Inventors: Bjarne Due Larsen, Jens Damsgaard Mikkelsen, Søren Neve